Bernstein reiterated a Buy rating and raised the price target for Gilead Sciences, citing that HIV performed better than expected.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bernstein reiterated a Buy rating and raised the price target for Gilead Sciences, citing that HIV performed better than expected.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Bernstein – The Memory of Paper
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyWhat Do Analysts Think About Gilead Sciences (GILD)? Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable growth stocks to buy. In a report released on August 21, Evan Seigerman from BMO
- Insider MonkeyGilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Scie